Live Salesforce, Inc. Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow Rezolute, Inc.

Get SEC filing alerts via email and in your feed for Rezolute, Inc.

RZLT

Rezolute, Inc.

About Rezolute, Inc.

Rezolute, Inc. is a late-stage biotech company developing therapies for rare hyperinsulinism conditions, including congenital and tumor-related hypoglycemia. Its lead asset, ersodetug, is a monoclonal antibody targeting insulin receptor activity, with potential to treat unmet medical needs in pediatric and adult patients. The company focuses on clinical development, regulatory approvals, and intellectual property to address significant market opportunities in rare disease therapeutics.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from Rezolute, Inc.

1
1
Rezolute, Inc. Rezolute Reports $16.2 Million Net Loss for Fiscal Quarter Ending March 31, 2026

Via official filing (AI summary) | 23 days ago | 0 comments

2
1
Rezolute, Inc. Rezolute Reports $40.9 Million Net Loss and Workforce Reduction Amid Clinical Trial Challenges

Via official filing (AI summary) | 4 months ago | 0 comments

3
1
Rezolute, Inc. Rezolute Reports $18.2 Million Net Loss and Increased Operating Expenses for Fiscal Quarter Ending September 30, 2025

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
Rezolute, Inc. Rezolute Reports $74.4 Million Net Loss for Fiscal Year Ending June 30, 2025

Via official filing (AI summary) | 9 months ago | 0 comments

5
1
Rezolute, Inc. Rezolute Reports $18.9 Million Net Loss and Increased R&D Expenses for Fiscal Quarter Ending March 31, 2025

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
Rezolute, Inc. Rezolute Reports $15.7 Million Net Loss and Increased R&D Expenses for Fiscal Quarter Ending December 31, 2024

Via official filing (AI summary) | over 1 year ago | 0 comments

7
1
Rezolute, Inc. Rezolute Reports Net Loss of $15.4M, Increased Expenses, and Decreased Cash Reserves in Q3 2024

Via official filing (AI summary) | over 1 year ago | 0 comments